Skip to main content

Table 1 Characteristics of patients in HIV care in a rural and an urban clinic, Zomba District, Malawi

From: The burden of hypertension, diabetes mellitus, and cardiovascular risk factors among adult Malawians in HIV care: consequences for integrated services

Characteristics

Total

Rural

Urban

P-value

n (%)

n (%)

n (%)

Number of patients

952

472 (49.6)

480 (50.4)

 

Gender

  Female

683 (71.7)

334 (70.8)

349 (72.7)

0.505

  Male

269 (28.3)

138 (29.2)

131 (27.3

 

Age in years (N = 952)

   

0.250

  18–34

210 (22.1)

111 (23.5)

99 (20.6)

 

  35–44

361 (37.9)

182 (38.6)

179 (37.3)

 

  45–54

238 (25.0)

105 (22.3)

133 (27.7)

 

   ≥ 55

143 (15.0)

74 (15.7)

69 (14.4)

 

Mean age (SD) in years

43.0 (10.2)

42.7 (10.6)

43.2 (9.8)

0.471

Educational status

  None

204 (21.5)

143 (30.3)

61 (12.7)

<0.001

  Standard 1–8

576 (60.6)

283 (60.0)

293 (61.2)

 

  Secondary & above

171 (18.0)

46 (9.8)

125 (26.1)

 

Household size mean (SD)

2.58 (1.26)

2.55 (1.17)

2.62 (1.35)

0.401

Employment status

  Employed

112 (11.8)

17 (3.6)

95 (19.8)

<0.001

  Unemployed

255 (26.8)

38 (8.1)

217 (45.2)

 

  Self Employed

585 (61.5)

417 (88.4)

168 (35.0)

 

Physical activity

  Vigorously active

854 (89.7)

458 (97.0)

396 (82.5)

<0.001

  Moderately active

90 (9.5)

11 (2.3)

79 (16.5)

 

  Inactive individuals

8 (0.8)

3 (0.6)

5 (1.0)

 

Dietary history

  Mean days of fruit consumption/wk (SD)

2.63 (2.06)

2.31 (1.87)

2.98 (2.20)

<0.001

  Mean servings of fruit/day (SD)

1.25 (0.76)

1.20 (0.74)

1.31 (0.79)

0.028

  Mean days of vegetables consumption/wk (SD)

5.13 (1.95)

4.51 (1.88)

5.73 (1.83)

<0.001

  Mean servings of vegetables/day (SD)

1.81 (0.49)

1.77 (0.50)

1.85 (0.47)

0.006

Tobacco

  Ever smoked tobacco

117 (12.3)

50 (10.6)

67 (14.0)

0.114

  Current tobacco smokers

34 (3.6)

19 (4.3)

15 (3.1)

0.454

  Daily tobacco smoker

25 (2.6)

15 (3.2)

10 (2.1)

0.291

  Current smokeless tobacco users

21 (2.2)

15 (3.2)

6 (1.3)

0.041

Alcohol

  Used alcohol in the past 30 days (current drinker)

61 (6.4)

33 (7.0)

28 (5.8)

0.466

  Used alcohol in the past 12 months

97 (10.2)

56 (11.9)

41 (8.5)

0.090

Self-report of previous stroke

  Yes

41 (4.3)

26 (5.5)

15 (3.1)

0.070

  No

909 (95.7)

445 (94.5)

464 (96.9)

 

Self-report of previous myocardial infarction

  Yes

211 (22.2)

113 (24.0)

98 (20.5)

0.190

  No

739 (77.8)

358 (76.0)

381 (79.5)

 

ART Status

  On ART

913 (95.9)

443 (93.9)

470 (97.9)

0.002

  Pre-ART

39 (4.1)

29 (6.1)

10 (2.1)

 

Mean HIV infection duration (SD), months

55.4 (31.7)

49.7 (32.2)

61.0 (30.2)

<0.001

Mean ART duration (SD), months

47.7 (29.3)

42.1 (29.0)

53.0 (28.7)

<0.001

CD4 count at ART initiation, mean (SD) (n = 632)

217.5 (114.6)

216.9 (121.0)

218.1 (108.2)

0.898

WHO stage at ART initiation

  WHO Stage 1

275 (30.1)

171 (38.6)

104 (22.1)

<0.001

  WHO Stage 2

306 (33.5)

139 (31.4)

167 (35.5)

 

  WHO Stage 3

270 (29.5)

110 (24.8)

160 (34.0)

 

  WHO Stage 4

63 (6.9)

23 (5.2)

40 (8.5)

 

Current ART Regimen

  2Aa

107 (11.7)

33 (7.5)

74 (15.7)

<0.001

  5Ab

775 (84.9)

397 (89.6)

378 (80.4)

 

  Other

31 (3.4)

13 (2.9)

18 (3.8)

 

Mean BMI (SD), kg/m2

21.9 (3.4)

21.3 (3.2)

22.6 (3.6)

<0.001

BMI categories, n (%)

  Under weight (<18.5 kg/m2)

102 (10.7)

65 (13.8)

37 (7.7)

<0.001

  Normal (18.5–25 kg/m2)

682 (71.6)

349 (73.9)

333 (69.4)

 

  Over weight (>25–30 kg/m2)

132 (13.9)

45 (9.5)

87 (18.1)

 

  Obesity (>30 kg/m2)

36 (3.8)

13 (2.8)

23 (4.8)

 

Waist to hip ratio, n (%)

  High

249 (26.9)

122 (27.1)

127 (26.6)

0.867

  Normal

678 (73.1)

328 (72.9)

350 (73.4)

 

Proteinuria

Normal (negative or trace)

928 (97.9)

470 (99.6)

458 (97.9)

0.001

  1+

13 (1.4)

2 (0.4)

11 (2.3)

 

  2+

7 (0.7)

0

7 (1.5)

 
  1. SD standard deviation, BMI body mass index
  2. a2A, generic single tablet formulation of zidovudine, lamivudine, nevirapine
  3. b5A, generic single tablet formulation of tenofovir, lamivudine, efavirenz